Details for Patent: 9,211,295
Summary for Patent: 9,211,295
| Title: | 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | 17α,21-Dihydroxypregna-4,9(11)-diene-3,20-dione and 17α,21-dihydroxypregna-4-ene-3,20-dione 17 and/or 21 esters having remarkable antiandrogenic activity are provided, along with methods of using these compounds and processes for their preparation. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Mauro Ajani, Luigi Moro | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Cassiopea SpA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US14/474,765 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 9,211,295: Claim Scope, Patent Landscape, and Generic-Entry Analysis for Cortexolone 17α-PropionateUS Patent 9,211,295 protects pharmaceutical use of cortexolone 17α-propionate, also known as clascoterone, in topical and certain broader pharmaceutical formulations for acne, alopecia, hirsutism, and seborrhea. The strongest practical coverage is directed to topical products containing clascoterone, particularly creams, gels, and liposomal formulations. The patent does not claim clascoterone as a chemical compound itself. The claims divide into two groups:
The patent is relevant to Winlevi, the FDA-approved clascoterone cream marketed by Cosmo Pharmaceuticals through its U.S. commercial arrangements. FDA approved Winlevi 1% cream for the topical treatment of acne vulgaris in patients 12 years and older in August 2020.[1] What drug and active ingredient does US Patent 9,211,295 cover?The claimed active ingredient is 17α-propionyloxy-21-hydroxy-pregna-4-ene-3,20-dione, commonly called cortexolone 17α-propionate or clascoterone.
Clascoterone is converted in the skin to cortexolone and is designed to inhibit androgen-receptor signaling locally. The claimed molecule is structurally distinct from corticosteroids such as hydrocortisone, despite sharing the steroid nucleus. What are the independent claims of US Patent 9,211,295?The patent contains three commercially important independent claim structures. Claim 1: Pharmaceutical formulationClaim 1 covers:
The claim is broad at the dosage-form level. It does not require a particular concentration, excipient, particle size, delivery system, or manufacturing process. A product may fall within claim 1 if it contains the claimed active ingredient in a topical pharmaceutical formulation with a pharmaceutically acceptable carrier and is labeled or technically suitable for one of the listed conditions. Claim 13: Treatment of hirsutismClaim 13 covers administering an effective amount of clascoterone to a patient requiring treatment for hirsutism. The independent claim does not expressly require topical administration. Dependent claims narrow the method to topical use and topical dosage forms. This structure creates a potentially broad method claim, but enforcement would require proof that the accused product is administered for hirsutism and that the use falls within the claim's treatment limitations. Claim 20: Treatment of seborrheaClaim 20 covers administering an effective amount of clascoterone to treat seborrhea. As with claim 13, the independent claim does not expressly require topical administration. Claims 21-26 narrow the method to topical treatment and specified formulation types. How do claims 1-12 protect topical clascoterone formulations?Claims 1-12 form a descending formulation hierarchy.
Claim 1 is the principal broad formulation claim. Claims 2-4 create alternative dosage-form branches. Claims 5-12 progressively narrow the cream branch by requiring specific excipients. The dependent claims use an open-ended formulation structure inherited from claim 1. A formulation containing additional excipients could still fall within the claims if it contains the required ingredients and otherwise meets the limitations. What formulations are protected by claims 5-12?Claims 5-12 are directed to a defined cream composition. The full combination in claim 12 includes:
The claims do not state quantitative ranges for these excipients. They also do not expressly require a 1% concentration of clascoterone. As a result, infringement analysis would depend on the claim construction of terms such as "effective amount," "cream," "pharmaceutically acceptable carrier," and "suitable for topical application." A generic or follow-on product could avoid claims 6-12 by omitting one or more required excipients. That strategy would not necessarily avoid claim 1 or claim 2, because claim 1 does not require the listed excipient package and claim 2 broadly covers a cream. Formulation design-around exposure
What do claims 13-19 protect for hirsutism?Claims 13-19 protect a treatment sequence for hirsutism:
The hirsutism claims cover the active ingredient and treatment purpose rather than a particular concentration or excipient system. A product label expressly directing use for hirsutism would create greater method-of-use exposure than a product labeled solely for acne. Inducement risk could also arise from promotional materials, physician instructions, clinical protocols, or other evidence showing an intent to encourage a claimed hirsutism use. A product's composition alone would not establish infringement of the hirsutism method claims without the required treatment or inducement facts. What do claims 20-26 protect for seborrhea?Claims 20-26 mirror the hirsutism claim structure for seborrhea:
The claims could be relevant to future clascoterone products for seborrheic dermatitis, seborrhea, or related androgen-responsive skin conditions, depending on the scope assigned to "seborrhea" and the product's labeling and use. Does US Patent 9,211,295 protect acne and alopecia treatment methods?Not directly through the method claims reproduced here. Claims 1-12 identify acne and alopecia as conditions for which the formulation is intended. Claims 13-26, however, recite treatment methods only for hirsutism and seborrhea. That distinction matters:
A court could evaluate whether the condition language in claim 1 is limiting and whether product labeling, technical characteristics, or marketing materials establish that the formulation is "for" one of the recited conditions. How broad is the patent's claim coverage?The patent has meaningful breadth at the formulation level but narrower breadth at the excipient level. Broadest practical protectionClaim 1 is the most commercially important claim because it does not require:
The principal required elements are the active ingredient, topical suitability, a pharmaceutically acceptable carrier, and one of four stated treatment purposes. Narrower protectionClaims 5-12 are materially narrower because they require specific cream excipients. They may provide fallback protection against products using the claimed excipient architecture, but they are easier to design around than claim 1. Claims 13 and 20 are broad in route because the independent claims do not expressly require topical administration. Their practical reach is limited by the need to prove treatment of the specified condition. What patent does not claim?Based on the supplied claims, US 9,211,295 does not expressly claim:
This distinction is important for freedom-to-operate analysis. A product can avoid the listed excipient claims while still implicating the broad formulation claim or separate later patents directed to concentration, vehicle, stability, manufacturing, or clinical use. What is the patent landscape around Winlevi and clascoterone?The clascoterone patent estate is expected to include multiple patent families rather than a single blocking patent. The relevant categories are:
US 9,211,295 should therefore be treated as one layer of the clascoterone estate. It is particularly relevant to formulation and certain therapeutic-use scenarios, but it should not be assumed to represent the entire U.S. blocking position for Winlevi. What is the Orange Book status of US Patent 9,211,295?A definitive Orange Book determination requires the current FDA Orange Book listing for the approved Winlevi product and its applicable patent-use codes. The patent's relevance cannot be established from the claim text alone. For regulatory strategy, the following questions control:
The Orange Book, FDA-approved labeling, and the patent's current USPTO record are the controlling sources for this analysis.[1,2] When does US Patent 9,211,295 lose exclusivity?The ordinary U.S. patent term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory adjustments.[3] The patent's operative expiration date should be taken from the current USPTO patent record and any applicable FDA patent-term-extension record. The grant date alone does not determine expiration. Patent expiry also does not eliminate all regulatory barriers. A generic applicant may face:
Are there Paragraph IV risks for a clascoterone generic?A generic applicant seeking approval before expiration of listed patents could submit an Abbreviated New Drug Application with a Paragraph IV certification against patents it believes are invalid, unenforceable, or not infringed.[4] For a topical clascoterone product, the principal Paragraph IV theories could include:
The most important distinction is between an ANDA product and its labeling. A generic seeking approval only for acne may have a stronger carve-out position against method claims directed to hirsutism or seborrhea, but it could remain exposed to formulation claims that include acne. Which companies are challenging the clascoterone patent estate?The supplied claim text does not establish the existence, identity, or status of a Paragraph IV challenger, ANDA litigation, inter partes review, post-grant review, or settlement agreement. A reliable competitive assessment must distinguish among:
These events have different legal and commercial consequences. A company identified in a patent database as an assignee, licensee, or applicant is not necessarily a litigation challenger. How strong is the patent estate for clascoterone?US 9,211,295 has moderate-to-strong practical value for products that use clascoterone in a conventional topical dosage form and are marketed for one of the listed conditions. Strength factors
Vulnerability factors
The strongest claim is likely claim 1 from a commercial infringement perspective. Claims 5-12 provide narrower fallback positions but are less likely to block every alternative vehicle. What generic launch scenarios exist?
What manufacturing and intellectual-property barriers remain?The patent claims supplied do not cover a manufacturing process. A competitor could therefore face a separate freedom-to-operate review for:
A generic applicant may be able to manufacture clascoterone without infringing US 9,211,295 while still encountering separate process or formulation patents. Trade secrets involving manufacturing parameters may also affect commercial replication without appearing in patent claims. Key Takeaways
FAQsDoes US Patent 9,211,295 claim Winlevi by brand name?No. The claims identify the active ingredient, cortexolone 17α-propionate, and specified formulations and uses. They do not use the Winlevi brand name. Can a clascoterone gel avoid the patent?Not necessarily. Claim 3 expressly covers a gel, and claim 1 broadly covers a topical clascoterone formulation with a pharmaceutically acceptable carrier. Can removing cetyl alcohol avoid all claims?Removing cetyl alcohol may avoid claim 6 and the claims depending from it. It would not necessarily avoid claims 1-4, which do not require cetyl alcohol. Does an acne-only generic avoid the hirsutism and seborrhea claims?It may reduce exposure to those method claims because the product would not be labeled for the claimed conditions. It would not necessarily avoid the formulation claims, which expressly include acne. Is a non-topical clascoterone product outside the patent?A non-topical product may avoid the topical formulation claims, but claims 13 and 20 do not expressly require topical administration in their independent form. The applicable claim scope would depend on the route, indication, and treatment facts. References
More… ↓ |
Drugs Protected by US Patent 9,211,295
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,211,295
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Italy | MI2001A1762 | Aug 10, 2001 |
International Family Members for US Patent 9,211,295
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 289318 | ⤷ Start Trial | |||
| Australia | 2002328956 | ⤷ Start Trial | |||
| Canada | 2454675 | ⤷ Start Trial | |||
| China | 1246328 | ⤷ Start Trial | |||
| China | 1541220 | ⤷ Start Trial | |||
| Germany | 60203013 | ⤷ Start Trial | |||
| Denmark | 1421099 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
